DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Prostate cancer
Disease landscape and forecast

Emerging therapies set to disrupt prostate cancer market
Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson & Johnson / Janssen Biotech / Janssen-Cilag / AstraZeneca) and Xtandi (Pfizer / Astellas) are cornerstone treatments for metastatic castrate-resistant prostate cancer (mCRPC). Several current and emerging therapies are also being positioned in the lucrative nonmetastatic CRPC and metastatic hormone-sensitive settings. The late-phase pipeline for mCRPC has also become more dynamic, with two PARP inhibitors (Johnson & Johnson’s Zejula and Pfizer’s Talzenna), four immune checkpoint inhibitors (Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo, Bristol-Myers Squibb/Ono Pharmaceutical’s Yervoy, Merck Sharp and Dohme’s Keytruda, and Roche/Genentech/Chugai’s Tecentriq), two kinase inhibitors (Array BioPharma / Roche / Genentech / Chugai’s ipatasertib and AstraZeneca’s capivasertib), one radioligand therapy (Novartis’ 177Lu-PSMA-617), and one angiogenesis inhibitor (Exelixis / Takeda / Ipsen’s Cabometyx) in Phase III development.

What does the future hold for the prostate cancer market?

Download the key insights to understand:

  • Current market dynamics
  • Market constraints
  • Current treatment dynamics
  • Unmet needs
  • Emerging pipeline drugs
Key Insights – Prostate Cancer
Key questions answered in this report
  • What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?
  • How is prostate cancer currently managed, and how will treatment practices change in the future?
  • What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning in the market? How will new market entrants fare through 2028?
  • What are the actionable remaining unmet needs affecting the management of prostate cancer? What are the key drug development and therapeutic opportunities?

If you’d like to see these insights for other markets, visit our report store to see our full range

Note – if your company has a DRG subscription you may be able to access this report by logging in, click here.